Search

Your search keyword '"Heathcote, J"' showing total 878 results
Start Over Author "Heathcote, J"
878 results on '"Heathcote, J"'

101. Providing scientific evidence: RCTs and beyond

Author

Sørensen, Thorkild I.A., Hadenque, A, Salerno, F, Bendtsen, F, Talwalkar, J, Heathcote, J, Blei, A.T.,Rodés,J, Franchis, R de, Sørensen, Thorkild I.A., Hadenque, A, Salerno, F, Bendtsen, F, Talwalkar, J, Heathcote, J, Blei, A.T.,Rodés,J, and Franchis, R de

Published
2006

103. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations

Author

Stone, John H., primary, Khosroshahi, Arezou, additional, Deshpande, Vikram, additional, Chan, John K. C., additional, Heathcote, J. Godfrey, additional, Aalberse, Rob, additional, Azumi, Atsushi, additional, Bloch, Donald B., additional, Brugge, William R., additional, Carruthers, Mollie N., additional, Cheuk, Wah, additional, Cornell, Lynn, additional, Castillo, Carlos Fernandez-Del, additional, Ferry, Judith A., additional, Forcione, David, additional, Klöppel, Günter, additional, Hamilos, Daniel L., additional, Kamisawa, Terumi, additional, Kasashima, Satomi, additional, Kawa, Shigeyuki, additional, Kawano, Mitsuhiro, additional, Masaki, Yasufumi, additional, Notohara, Kenji, additional, Okazaki, Kazuichi, additional, Ryu, Ji Kon, additional, Saeki, Takako, additional, Sahani, Dushyant, additional, Sato, Yasuharu, additional, Smyrk, Thomas, additional, Stone, James R., additional, Takahira, Masayuki, additional, Umehara, Hisanori, additional, Webster, George, additional, Yamamoto, Motohisa, additional, Yi, Eunhee, additional, Yoshino, Tadashi, additional, Zamboni, Giuseppe, additional, Zen, Yoh, additional, and Chari, Suresh, additional

Published
2012
Full Text
View/download PDF

108. Multicentred international review of orbital exenteration and reconstruction in oculoplastic and orbit practice

Author

Zhang, Ze, Ho, Son, Yin, Vivian, Varas, Gonzalo, Rajak, Saul, Dolman, Peter J, McNab, Alan, Heathcote, J Godfrey, and Valenzuela, Alejandra

Abstract

BackgroundOrbital exenteration is a disfiguring procedure reserved for life-threatening malignancies. This study examines the clinical course and outcomes of a large series of patients who underwent orbital exenteration for malignant periocular neoplasms.MethodsThis is a retrospective review of patients who underwent orbital exenteration from 1 July 2005 to 30 June 2015 at four tertiary referral centres in the USA, Australia and Canada. Demographics, indication for surgery, pathology, surgical technique, reconstruction type and outcomes were reviewed.ResultsOrbital exenteration was performed on 102 patients. The mean age at surgery was 67.5 years. The most common malignant tumours encountered were squamous cell carcinoma, melanoma and basal cell carcinoma. Seventy-six patients (75%) underwent reconstruction with a local myocutaneous flap, twelve with partial-thickness skin grafts (PTSG), or split skin graft, two had a free flap, and one had a dermis fat graft. Sixteen patients had combined procedures of two of the above. Complete removal of the tumour was achieved with clear margins in 81 cases. Of all patients, 72% were alive at 48 months or more.ConclusionThe majority of orbital exenterations performed in this series were secondary to periocular malignancies with unsuccessful/insufficient previous treatments. Regional myocutaneous flaps, PTSG, full-thickness skin grafts and dermis fat grafts were all highly effective and durable reconstructive options, and were able to withstand radiation therapy without complications.

Published
2018
Full Text
View/download PDF

117. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

Author

Nunen, A.B. van, Schalm, S.W. (Solko), Hansen, B.E. (Bettina), Suh, D.J., Lohr, H.F., Chemello, L. (Liliana), Fontaine, H., Heathcote, J., Song, B.C., Janssen, H.L.A. (Harry), Man, R.A. (Robert) de, Nunen, A.B. van, Schalm, S.W. (Solko), Hansen, B.E. (Bettina), Suh, D.J., Lohr, H.F., Chemello, L. (Liliana), Fontaine, H., Heathcote, J., Song, B.C., Janssen, H.L.A. (Harry), and Man, R.A. (Robert) de

Abstract

Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients. Preliminary reports on the durability of HBeAg seroconversion following lamivudine are contradictory. We investigated the durability of response following IFN, lamivudine, or IFN-lamivudine combination therapy in a meta-analysis of individual patient data. PATIENTS AND METHODS: Twenty four centres included 130 patients in total with an HBeAg seroconversion (HBeAg negative, antibodies to hepatitis B e antigen positive) at the end of antiviral therapy: 59 with lamivudine, 49 with interferon, and 22 with combination therapy. Relapse was defined as confirmed reappearance of HBeAg. RESULTS: The three year cumulative HBeAg relapse rate by the Kaplan-Meier method was 54% for lamivudine, 32% for IFN, and 23% for combination therapy (p=0.01). Cox regression analysis identified pretreatment hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT), sex, and therapy as independent predictive factors of post-treatment relapse; Asian race, previous therapy, centre, and type of study were not predictive of relapse. The relative HBeAg relapse risk of lamivudine compared with IFN therapy was 4.6 and that of combination therapy to IFN therapy 0.7 (p(overall)=0.01). CONCLUSIONS: The durability of HBeAg seroconversion following lamivudine treatment was significantly lower than that following IFN or IFN-lamivudine combination therapy. The risk of relapse after HBeAg seroconversion was also related to pretreatment levels of serum ALT and HBV DNA, but independent of Asian race.

Published
2003

118. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis BL relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

Author

Nunen, AB, Hansen, Bettina, Suh, DJ, Löhr, HF, Chemello, L, Fontaine, H, Heathcote, J, Song, BC, Janssen, HLA, de Man, Rob, Schalm, Solko, Nunen, AB, Hansen, Bettina, Suh, DJ, Löhr, HF, Chemello, L, Fontaine, H, Heathcote, J, Song, BC, Janssen, HLA, de Man, Rob, and Schalm, Solko

Published
2003

121. 4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR

Author

Berg, T., primary, McHutchison, J.G., additional, Adda, N., additional, Poordad, F., additional, Shiffman, M.L., additional, Ferenci, P., additional, Heathcote, J., additional, Pawlotsky, J.-M., additional, Zeuzem, S., additional, Reesink, H., additional, Dusheiko, G., additional, Martin, E., additional, Alexanderian, D., additional, George, S., additional, and Muir, A.J., additional

Published
2010
Full Text
View/download PDF

124. Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB)

Author

Buggisch, P, primary, Manns, M, additional, Mauss, S, additional, Berg, T, additional, Teuber, G, additional, Petersen, J, additional, Schuchmann, M, additional, Zeuzem, S, additional, Marcellin, P, additional, Heathcote, J, additional, Sorbel, J, additional, and Rousseau, F, additional

Published
2009
Full Text
View/download PDF

128. 1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

Author

Manns, M., primary, Muir, A., additional, Adda, N., additional, Jacobson, I., additional, Afdhal, N., additional, Heathcote, J., additional, Zeuzem, S., additional, Reesink, H., additional, Terrault, N., additional, Bsharat, M., additional, George, S., additional, McHutchison, J., additional, and Di Bisceglie, A., additional

Published
2009
Full Text
View/download PDF

131. Ténofovir disoproxil sous forme de fumarate (TDF) pour le traitement de l’hépatite B chronique chez des patients AgHBe-positif : résultats à 72 semaines et données à 24 semaines après remplacement d’adéfovir dipivoxil par TDF (étude 103)

Author

Couzigou, P., primary, Marcellin, P., additional, Pol, S., additional, Bronowicki, J.-P., additional, Benhamou, Y., additional, Mathurin, P., additional, Trepo, C., additional, Zarski, J.P., additional, Habersetzer, F., additional, Bourlière, M., additional, Heathcote, J., additional, and Rousseau, F., additional

Published
2008
Full Text
View/download PDF

134. Tenofovir DF (TDF) showed superior antiviral efficacy to adefovir dipivoxil in a randomized, double-blind, study for the treatment of HBeAg-positive chronic hepatitis B (CHB)

Author

Andreone, P., primary, Heathcote, J., additional, Rizzetto, M., additional, Gane, E., additional, DeMan, R., additional, Lee, S., additional, Flisiak, R., additional, Sorbel, J., additional, Anderson, J., additional, Mondou, E., additional, and Rousseau, F., additional

Published
2008
Full Text
View/download PDF

137. 988 SUSTAINED VIRAL RESPONSE (SVR) IS DEPENDENT ON BASELINE CHARACTERISTICS IN THE RETREATMENT OF PREVIOUS ALFA INTERFERON/RIBAVIRIN (I/R) NONRESPONDERS (NR): FINAL RESULTS FROM THE EPIC3 PROGRAM

Author

Poynard, T., primary, Schiff, E., additional, Terg, R., additional, Otero, R. Moreno, additional, Flamm, S., additional, Schmidt, W., additional, Berg, T., additional, Goncales, F., additional, Heathcote, J., additional, Diago, M., additional, McGarrity, T., additional, Bedossa, P., additional, Deng, W., additional, Mukhopadhyay, P., additional, Griffel, L., additional, Burroughs, M., additional, Brass, C., additional, and Albrecht, J.K., additional

Published
2008
Full Text
View/download PDF

138. 689 LACK OF INFLUENCE OF BASELINE GENOTYPE ON ANTIVIRAL RESPONSE IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION RECEIVING TENOFOVIR DF 300 MG QD FOR 1 YEAR

Author

Gane, E., primary, Benhamou, Y., additional, Gladysz, A., additional, Zeuzem, S., additional, Germanidis, G., additional, Heathcote, J., additional, Marcellin, P., additional, Sorbel, J., additional, Borroto-Esoda, K., additional, Rousseau, F., additional, and Snow-Lampart, A., additional

Published
2008
Full Text
View/download PDF

139. 72 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 103)

Author

Heathcote, J., primary, George, J., additional, Gordon, S., additional, Bronowicki, J.P., additional, Sperl, J., additional, Williams, R., additional, Martin, P., additional, Beniowski, M., additional, Sorbel, J., additional, Anderson, J., additional, Mondou, E., additional, Snow, A., additional, and Rousseau, F., additional

Published
2008
Full Text
View/download PDF

141. 822 PLATELET COUNT PREDICTS SUSTAINED VIRAL RESPONSE (SVR) IN THE RE-TREATMENT OF PREVIOUS INTERFERON/RIBAVIRIN NON-RESPONDERS (NR): RESULTS FROM THE EPIC3 PROGRAM

Author

Poynard, T., primary, Schiff, E., additional, Terg, R., additional, Moreno-Otero, R., additional, Flamm, S., additional, Schmidt, W., additional, Berg, T., additional, Goncales Jr, F., additional, Heathcote, J., additional, Diego, M., additional, McGarrity, T., additional, Bedossa, P., additional, Deng, W., additional, Mukhopadhyay, P., additional, Griffel, L., additional, Burroughs, M., additional, Brass, C., additional, and Albrecht, J.K., additional

Published
2008
Full Text
View/download PDF

142. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

Author

Schalm, S.W. (Solko), Heathcote, J., Cianciara, J., Farrell, G., Sherman, M.E. (Mark), Willems, B., Dhillon, A., Moorat, A., Barber, J. (Judy), Gray, D.F., Schalm, S.W. (Solko), Heathcote, J., Cianciara, J., Farrell, G., Sherman, M.E. (Mark), Willems, B., Dhillon, A., Moorat, A., Barber, J. (Judy), and Gray, D.F.

Abstract

BACKGROUND, AIM, AND METHODS: Alpha interferon is the generally approved therapy for HBe antigen positive patients with chronic hepatitis B, but its efficacy is limited. Lamivudine is a new oral nucleoside analogue which potently inhibits hepatitis B virus (HBV) DNA replication. To investigate the possibility of an additive effect of interferon-lamivudine combination therapy compared with interferon or lamivudine monotherapy, we conducted a randomised controlled trial in 230 predominantly Caucasian patients with hepatitis B e antigen (HBeAg) and HBV DNA positive chronic hepatitis B. Previously untreated patients were randomised to receive: combination therapy of lamivudine 100 mg daily with alpha interferon 10 million units three times weekly for 16 weeks after pretreatment with lamivudine for eight weeks (n=75); alpha interferon 10 million units three times weekly for 16 weeks (n=69); or lamivudine 100 mg daily for 52 weeks (n=82). The primary efficacy end point was the HBeAg seroconversion rate at week 52 (loss of HBeAg, development of antibodies to HBeAg and undetectable HBV DNA). RESULTS: The HBeAg seroconversion rate at week 52 was 29% for the combination therapy, 19% for interferon monotherapy, and 18% for lamivudine monotherapy (p=0.12 and p=0.10, respectively, for comparison of the combination therapy with interferon or lamivudine monotherapy). The HBeAg seroconversion rates at week 52 for the combination therapy and lamivudine monotherapy were significantly different in the per protocol analysis (36% (20/56) v 19% (13/70), respectively; p=0.02). The effect of combining lamivudine and interferon appeared to be most useful in patients with moderately elevated alanine aminotransferase levels at baseline. Adverse events with the combination therapy were similar to interferon monotherapy; patients receiving lamivudine monotherapy had significantly fewer adverse events. CONCLUSIONS: HBeAg seroconversion rates at one year were similar for lamivudine monotherapy (5

Published
2000

147. P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy

Author

Hadziyannis, S.J., primary, Tassopoulos, N.C., additional, Chang, T., additional, Heathcote, J., additional, Kitis, G., additional, Rizzetto, M., additional, Marcellin, P., additional, Lim, S., additional, Goodman, Z., additional, Arterburn, S., additional, Ma, J., additional, Borroto-Esoda, K., additional, Mondou, E., additional, and Chuck, S.L., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results